Aerie Pharmaceuticals (AERI) Earning Somewhat Favorable News Coverage, Analysis Finds

The FDA published its take on Aerie's filing ahead of Friday's advisory committee meeting

The FDA published its take on Aerie's filing ahead of Friday's advisory committee meeting

33 funds opened positions while 48 raised stakes. Thrivent Financial For Lutherans accumulated 95,980 shares. Neuberger Berman Gru Llc, a New York-based fund reported 12,500 shares. Moreover, Waddell And Reed Inc has 0.02% invested in Aerie Pharmaceuticals Inc (NASDAQ:AERI). Ny State Common Retirement Fund stated it has 0% in Aerie Pharmaceuticals Inc (NASDAQ:AERI). 386 are held by Mufg Americas Corp. Royal National Bank Of Canada invested in 77,462 shares. Endurant Cap LP stated it has 0.79% in Aerie Pharmaceuticals Inc (NASDAQ:AERI). The total value of its holdings increased 23.2%. Tudor Inv Corporation Et Al has 0.02% invested in Aerie Pharmaceuticals Inc (NASDAQ:AERI). 3,019,268 shares of the stock were exchanged. The stock of Aerie Pharmaceuticals Inc (NASDAQ:AERI) has "Buy" rating given on Wednesday, August 2 by Cowen & Co. The Harvey Capital Management Inc holds 26,700 shares with $1.40 million value, down from 57,100 last quarter. 20,662 are owned by Proshare Advsrs. 20,000 shares valued at $1.12M were sold by Foresite Capital Management II - LLC on Friday, May 26.

Aerie Pharmaceuticals Inc (NASDAQ:AERI) had its price objective boosted by equities research analysts at Needham & Company LLC from $58.00 to $65.00 in a research note issued on Thursday. This gauge is crucial in determining whether investors are moved toward the direction of buying more of the stock, or else doing the contradictory side and selling more of the stock. The 1-year high was reported on Oct, 12 by The company has an average rating of "Buy" and an average price target of $66.62.

The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. About 801 shares traded. AERI is down around 42.1% from its 12-month high of $32.05 notched on Nov 03, 2016 but is -10.75% above its highest point the past 12 months of $61.3 a share. It has outperformed by 163.50% the S&P500.

Analysts await Aerie Pharmaceuticals Inc (NASDAQ:AERI) to report earnings on November, 1. They expect $-0.79 earnings per share, up 2.47 % or $0.02 from last year's $-0.81 per share. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by $0.02. Two analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Therefore 100% are positive. In general, more thrust is placed on most recent actions by assigning higher weights to it than those assigned to past movements. The stock now has an average rating of "Buy" and a consensus price target of $67.46. Federated Investors Inc. PA boosted its stake in Aerie Pharmaceuticals by 88.7% in the fourth quarter. Canaccord Genuity reaffirmed a "buy" rating and set a $56.00 price target on shares of Aerie Pharmaceuticals in a research note on Tuesday, April 18th. The firm presently has a "buy" rating on the stock. Cantor Fitzgerald maintained it with "Buy" rating and $30 target in Friday, August 7 report. Canaccord Genuity reinitiated it with "Buy" rating and $50 target in Tuesday, December 20 report. The rating was maintained by JP Morgan on Friday, March 11 with "Overweight". The company was maintained on Wednesday, October 11 by Stifel Nicolaus. Mizuho reiterated a "buy" rating and set a $70.00 price target on shares of Aerie Pharmaceuticals in a research note on Monday, October 2nd. That puts the market capitalization at $14.7 bln. The firm has "Outperform" rating given on Thursday, September 15 by RBC Capital Markets. "(AERI) Has Jumped To A New High On FDA News" on October 11, 2017.

Hudson Technologies Inc. (NASDAQ:HDSN) stock is experiencing unusual volume during today's trading.

Aerie Pharmaceuticals, Inc., launched on June 22, 2005, is a clinical-stage pharmaceutical company. (AERI) . Average true range (ATR-14) of the company is at 2.61. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. It now has negative earnings. Its products include xMax system, an end-to-end Internet protocol (IP) network solution.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.